stockrow
Saturday 7 November 2026
Export ABPO’s income statement to Excel — free account
Abpro Holdings Inc.
ABPO Healthcare Biotechnology
Abpro Holdings Inc.’s revenue for fiscal 2024 (year ended December 2024) was $183,000.00, up 50.0% from fiscal 2023.
- EPS
- +89.3%
- Free cash flow
- −0.48%
Quarter to June 2026, against a year earlier
0.58
0.02
+3.57%
Follow ABPO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 0 | — | — | +50.0% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | — | — | 0.0 pt | ||||||
| EBT | — | — | — | — | — | 0 | 2 | (12) | (7) | (3) | 2 | +533.1% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | (9,595.08) | (3,951.91) | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | — | 0 | 1 | (12) | (7) | (3) | 2 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.19 | 0.23 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | 3.55 | (18.37) | (22.22) | (1.30) | 1.06 | n/m | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (4.74) | (11.62) | (11.58) | (2.69) | (1.12) | n/m | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | (0.08) | 0.00 | 0.01 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (4.74) | (11.69) | (11.58) | (2.68) | (1.12) | n/m | ||||||
| Book value | — | — | — | — | — | 0.00 | (44.75) | (138.81) | (19.16) | (3.71) | (0.51) | n/m | ||||||
| Shares, m | — | — | — | — | — | 38 | 0 | 1 | 1 | 2 | 4 | (50.6%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.55 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.12 | (6.78) | — | 0.12 | (3.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (1) | (7) | (9) | (6) | (7) | +71.8% | |||||
| Capex | — | — | — | — | — | — | — | 0 | — | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (1) | (7) | (9) | (6) | (7) | +71.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | (1) | (14) | (16) | (8) | (3) | +123.6% | |||||
| Net debt | — | — | — | — | — | 0 | 0 | (1) | (3) | 0 | (4) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | 0 | (11) | (88) | (15) | (8) | (3) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | 0.57 | (7.46) | (434.36) | (101.05) | 46.10 | (101.0) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | (15.90) | 23.50 | 33.68 | 24.90 | (20.18) | +24.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 6 | 3 | — | (50.0%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.03 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Sep 2024 · fundamentals updated 26 Oct 2026
Abpro Holdings Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OGEN Oragenics, Inc. | $1.6M | — (loss-making) | — (loss-making) | −75.33% (below 0%: shrinking) | n/m | −66.37% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| VRAX Virax Biolabs Group Limited | $1.6M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | Compare |
| KAPA Kairos Pharma, Ltd. | $1.5M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| ABPO Abpro Holdings Inc. | $1.4M | 0.5× | — | — | n/m | −0.48% (below 0%: shrinking) | 100.00% | 0.00% | |
| KPTI Karyopharm Therapeutics Inc. | $1.4M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| ELAB PMGC Holdings Inc. | $1.3M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | Compare |
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $1.4M | — | — | +34.31% | — | −29.52% | 63.14% | 0.00% |
Pay and ownership Proxy statement filed 8 September 2025
Ownership
Directors and executive officers, together
13.70%
Abpro Bio International, Inc.
20.60%
Atlantic Coastal Acquisition Management II LLC
18.40%
Ian Chan
12.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement